According to filings with the U.S. Securities and Exchange Commission, Solarea Bio is raising $25,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Gerardo Toledo played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Solarea Bio
Solarea Bio is a clinical-stage biotechnology company in Cambridge, MA developing plant-based microbial solutions to some of the worlds largest health problems. Solarea was founded in 2017 by a group of scientists and entrepreneurs eager to radically alter our understanding of the human microbiome and utilize its power to improve human health. The Solarea breakthrough came from the combined efforts of the company’s co-founders who established a link between the discovery of an untapped source of microorganisms with probiotic potential in healthy foods, and their applications in inflammatory processes including the gut-musculoskeletal axis. Using powerful genomic and bioinformatic tools, Solarea is mining its novel microbial strain collection to identify synergistic combinations of microbes and prebiotic plant fibers to develop solutions for patients suffering from inflammatory processes.

To learn more about Solarea Bio, visit http://www.solareabio.com/

Contact:
Gerardo Toledo, Chief Executive Officer
617-497-4611
https://www.linkedin.com/in/gerardo-v-toledo-2007411/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.